New antisense oligonucleotide therapies reach first base in ALS
- PMID: 35075291
- DOI: 10.1038/s41591-021-01629-7
New antisense oligonucleotide therapies reach first base in ALS
Comment on
-
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.Nat Med. 2022 Jan;28(1):117-124. doi: 10.1038/s41591-021-01557-6. Epub 2021 Dec 23. Nat Med. 2022. PMID: 34949835 Free PMC article.
-
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.Nat Med. 2022 Jan;28(1):104-116. doi: 10.1038/s41591-021-01615-z. Epub 2022 Jan 24. Nat Med. 2022. PMID: 35075293 Free PMC article.
References
-
- Deng, H. X. et al. Science 261, 1047–1051 (1993). - DOI
-
- Rosen, D. R. et al. Nature 362, 59–62 (1993). - DOI
-
- Finkel, R. S. et al. N. Engl. J. Med. 377, 1723–1732 (2017). - DOI
-
- Mercuri, E. et al. N. Engl. J. Med. 378, 625–635 (2018). - DOI
-
- Tran, H. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01557-6 (2021). - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
